**Title:** Positron Emission Tomography (NaF-18) to Identify Bone Metastasis of Cancer (CAG-00065R2)

**Decision:** Centers for Medicare & Medicaid Services (CMS) has determined that the evidence is sufficient to determine that use of a NaF-18 positron emission tomography (PET) scan to identify bone metastasis of cancer is not reasonable and necessary to diagnose or treat an illness or injury or to improve the functioning of a malformed body member and, therefore, is not covered.

CMS shall continue the requirement for coverage with evidence development (CED) for NaF-18 PET to identify bone metastasis of cancer contained in section 220.6.19B of the Medicare National Coverage Determinations Manual for 24 months from the final date of this decision. This extension is to allow confirmatory analyses to be performed and resulting evidence to be published.

All other uses and clinical indications for NaF-18 PET are nationally non-covered.

**What this means:** The use of NaF-18 PET scan to identify bone metastasis for cancer is not covered. However, Medicare shall continue to provide coverage for those members who are in a qualifying clinical trial for 24 months after 12/15/2015.

**Effective:** 12/15/2015

This announcement can be found at: [Decision Memo for Positron Emission Tomography (NaF-18) to Identify Bone Metastasis of Cancer (CAG-00065R2)](Decision%20Memo%20for%20Positron%20Emission%20Tomography%20(NaF-18)%20to%20Identify%20Bone%20Metastasis%20of%20Cancer%20(CAG-00065R2))

HealthPartners MSHO is a health plan that contracts with both Medicare and the Minnesota Medical Assistance (Medicaid) program to provide benefits of both programs to enrollees. HealthPartners Freedom is a Cost plan with a Medicare contract. Enrollment in HealthPartners depends on contract renewal.

H2462_90242 IR Approved 06/2015
H2422_90242 IR Approved 07/2015